AbbVie Wins FDA Approval to Start Skyrizi at Home: What the Crohn's Decision Means for ABBV Stock

The FDA approved an at-home way to start one of AbbVie's biggest drugs on October 23, 2026 — and Wall Street barely blinked. AbbVie (NYSE: ABBV) closed Friday at $285.64, up just $0.45, or 0.16%, after the U.S. Food and Drug Administration approved a subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease. Patients can now begin Skyrizi at home instead of starting with intravenous infusions in a clinic.

What happened: Skyrizi induction can now start at home

The FDA approved subcutaneous (SC) induction for Skyrizi on October 23, 2026. Under the new regimen, patients receive 720 mg delivered by an on-body injector (OBI) induction pack at weeks 0, 2, 4 and 8, then continue with OBI maintenance dosing once every eight weeks starting at week 12. The previously approved intravenous option — 600 mg at weeks 0, 4 and 8 — remains available, so doctors and patients now choose between a clinic-based start and a fully at-home start.

The FDA also approved a second, quieter change the same day: an update to Skyrizi's U.S. prescribing information across all indications. The revised warning language lets healthcare providers use clinical judgment when deciding whether tuberculosis (TB) testing is needed before treatment. There is no longer a mandatory TB test before starting Skyrizi.

The trial behind it: AFFIRM hit both main goals at week 12

The approval rests on the Phase 3 AFFIRM study, which randomized 274 adults with moderately to severely active Crohn's disease in a 2-to-1 ratio to subcutaneous Skyrizi or placebo. About 65% of participants had already failed advanced therapies, making it a largely treatment-refractory population.

At week 12, Skyrizi met both co-primary endpoints with statistical significance (p<0.001):

Clinical remission: 56% on Skyrizi vs. 30% on placebo
Endoscopic response: 43% vs. 15%
Endoscopic remission (secondary): 26% vs. 11%

Results were strongest in patients who had not previously failed advanced therapy: 74% reached clinical remission vs. 27% on placebo, and 60% achieved endoscopic response vs. 15%. Patients with prior advanced-therapy failure also responded better than placebo (45% vs. 31% remission). AbbVie said the safety profile was generally consistent with Skyrizi's established profile in Crohn's disease, with no new safety risks identified.

Why it's blowing up

Skyrizi is not a niche product — it is one of the engines of a company with a market value of roughly $511 billion, and it is already approved in the U.S. for Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. Any change that makes a blockbuster easier to start gets attention from both the medical and investing communities, and this one removes a real friction point: induction previously meant IV infusions, while maintenance was already at home with the OBI, a device first introduced for Crohn's maintenance in 2022.

Convenience data helps the story travel. AbbVie cited a real-world survey of 186 people with Crohn's disease in which 88% found the OBI easy to use, and a survey of 352 adults with inflammatory bowel disease in which 87% were satisfied or highly satisfied with the OBI, compared with 71% for an autoinjector. Lead AFFIRM investigator Millie D. Long, M.D., of the University of North Carolina at Chapel Hill, framed it simply: patients ask whether a treatment works and how it fits into their lives — and, in her words, this approval answers the second question.

Why did ABBV stock barely move?

The muted reaction — a 0.16% gain on a day the Dow fell 1.23% — has a straightforward explanation. This approval expands how an already-approved drug is given; it does not add a new indication or a new patient population. AbbVie submitted the application on April 27, 2026, so the decision, arriving just under six months later, was widely expected to be a matter of timing rather than a binary surprise. In relative terms, holding essentially flat while the broader market sold off was a quietly defensive performance for the stock.

What's next

Attention now shifts to uptake: how quickly gastroenterologists adopt at-home induction, whether the simpler start helps Skyrizi compete for earlier-line Crohn's patients — the subgroup with the strongest AFFIRM numbers — and whether the TB-testing flexibility speeds up treatment starts across Skyrizi's other indications. This post reports what happened and how markets reacted; it is not financial advice, and nothing here is a recommendation to buy, sell or hold any security.

Sources

FAQ

What did the FDA approve for Skyrizi on October 23, 2026?

The FDA approved a subcutaneous induction regimen for Skyrizi (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease, allowing patients to start treatment at home with an on-body injector instead of IV infusions.

How is the new at-home Skyrizi induction dosed?

Patients receive 720 mg by on-body injector at weeks 0, 2, 4 and 8, then continue maintenance dosing with the same device once every eight weeks from week 12. The IV induction option (600 mg at weeks 0, 4 and 8) remains available.

What did the Phase 3 AFFIRM trial show?

In 274 patients, Skyrizi beat placebo on both co-primary endpoints at week 12: clinical remission of 56% vs. 30% and endoscopic response of 43% vs. 15%, with no new safety risks reported.

What changed about TB testing for Skyrizi?

The FDA also updated Skyrizi's prescribing information across all indications so providers can use clinical judgment on whether TB testing is needed before treatment — a TB test is no longer mandatory before starting.